Biomarkers in the Etiology of Idiopathic Intracranial Hypertension
NCT ID: NCT06059703
Last Updated: 2024-05-28
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
NA
Total Enrollment
60 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-11-27
Study Completion Date
2026-03-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Idiopathic intracranial hypertension (IIH) is a condition characterized by an increase in intracranial pressure (ICP), papilledema with a risk of permanent visual loss, and severe headaches that profoundly affect quality of life.
To date the exact pathophysiology of IIH remains unknown. IIH is considered a complex neurometabolic and neuroendocrine disorder, favored by female gender, and obesity.
In the majority of patients (80% of the cases) IIH is associated with obstruction of cerebral venous drainage with stenosis of the transverse sinus. This stenosis may be the main underlying cause in the so-called "venogenic" form of IIH. Equally, in the absence of a stenosis, obstruction may occur when otherwise normal venous sinuses are compressed by the increased ICP, the so-called "non-venogenic" form of IIH. An innovative treatment of IIH with associated venous stenosis includes stenting of the transverse sinus stenosis. This strategy may allow resolution of papilledema and ICP reduction rates up to 80%.
Although the pathogenesis of IIH is still poorly understood, inflammatory mechanisms, autoimmune reactions, and hormonal abnormalities of notably androgens, have been proposed to contribute to its pathophysiology. The function of the blood-brain barrier (BBB) has been studied by determining the prevalence of extravasation of endogenous proteins such as fibrinogen.
A growing body of the literature shows a correlation between increased ICP and metabolic/hormonal changes.
The improvement of IIH treated with acetazolamide and/or stenting appears to correlate with the reduction of ICP. Yet the association of this reduction with metabolic changes at the peripheral and central blood level as well as the CSF remains unclear. The search for specific inflammatory, immunological and hormonal biomarkers in patients with IIH and their variation in relation to the ICP should provide a better understanding of its etiology.
To date the exact pathophysiology of IIH remains unknown. IIH is considered a complex neurometabolic and neuroendocrine disorder, favored by female gender, and obesity.
In the majority of patients (80% of the cases) IIH is associated with obstruction of cerebral venous drainage with stenosis of the transverse sinus. This stenosis may be the main underlying cause in the so-called "venogenic" form of IIH. Equally, in the absence of a stenosis, obstruction may occur when otherwise normal venous sinuses are compressed by the increased ICP, the so-called "non-venogenic" form of IIH. An innovative treatment of IIH with associated venous stenosis includes stenting of the transverse sinus stenosis. This strategy may allow resolution of papilledema and ICP reduction rates up to 80%.
Although the pathogenesis of IIH is still poorly understood, inflammatory mechanisms, autoimmune reactions, and hormonal abnormalities of notably androgens, have been proposed to contribute to its pathophysiology. The function of the blood-brain barrier (BBB) has been studied by determining the prevalence of extravasation of endogenous proteins such as fibrinogen.
A growing body of the literature shows a correlation between increased ICP and metabolic/hormonal changes.
The improvement of IIH treated with acetazolamide and/or stenting appears to correlate with the reduction of ICP. Yet the association of this reduction with metabolic changes at the peripheral and central blood level as well as the CSF remains unclear. The search for specific inflammatory, immunological and hormonal biomarkers in patients with IIH and their variation in relation to the ICP should provide a better understanding of its etiology.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diagnostic and Prognostic Biomarkers of Idiopathic Intracranial Hypertension
NCT04032379
Benign Intracranial Hypertension
RECRUITING
Assessment of Autonomic Neuronal Changes During Moderate Rise of Intracranial Pressure in Human
NCT01776801
Increased Intracranial Pressure Disorders
COMPLETED
NA
Assessment of ICP in Idiopathic Intracranial Hypertension Using Transocular Ultrasound and Transcranial Doppler
NCT04314128
Idiopathic Intracranial Hypertension
COMPLETED
NA
Quantitative D-dimer Level and Anticoagulant Therapy in Idiopathic Intracranial Hypertension
NCT03963336
Idiopathic Intracranial Hypertension
COMPLETED
EARLY_PHASE1
Idiopathic Intracranial Hypertension Treatment Trial
NCT01003639
Idiopathic Intracranial Hypertension
COMPLETED
PHASE2/PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Idiopathic intracranial hypertension (IIH) is a condition characterized by increased intracranial pressure (ICP) of unknown cause, papilledema with the risk of permanent visual impairment, and severe headaches that profoundly impair quality of life, often becoming irreversible despite resolution of the IIH and disappearance of the papilledema.
IIH is diagnosed using the modified Dandy criteria,based on increased ICP (\>25 cm H2O on lumbar puncture (LP) performed in the lateral decubitus), papilledema, normal cerebrospinal fluid (CSF) and brain imaging that rules out all other causes of intracranial hypertension.
IIH is attracting growing interest among clinicians as its incidence and prevalence increases. IIH predominates in women of childbearing age with increased body mass index (BMI) . In the United Kingdom its incidence has doubled in 14 years, rising from 3.5 per 100,000 to 7.69 per 100,000 in the female population between 2002 and 2016 (+ 108%)
To date, the exact pathophysiology of IIH remains unknown. IIH is considered to be a complex neurometabolic and neuroendocrine disorder favored by female gender and obesity. Hypothesized mechanisms include inflammatory, autoimmune and hormonal abnormalities, of notably androgens.
In the majority of patients (80% of the cases) IIH is associated with obstruction of cerebral venous drainage with bilateral stenosis of the transverse sinus. This stenosis may be the main underlying cause in the so-called "venogenic" form of IIH. Equally, in the absence of a stenosis, obstruction may occur when otherwise normal venous sinuses are compressed by the increased ICP, the so-called "non-venogenic" form of IIH.
The therapeutic management of IIH has a triple objective: i) to treat the underlying cause(s); ii) to protect vision, and iii) to reduce the impact of headaches. Unfortunately, current treatments (weight loss, drug therapy with acetazolamide or Diamox, and/or anti-migraine treatment) are not very effective. It has been argued to favor treatments targeted directly at the cause of the increased ICP, and therefore at its etiology. A promising innovative treatment of venogenic IIH includes stenting of the transverse sinus stenosis. It has been associated with papilledema and ICP reduction rates up to 80% .
However, venous stenosis is probably not the only underling mechanism of increased ICP. Accordingly, the role of metabolic, hormonal and inflammatory mechanisms requires further investigation. It has been found that serum levels of tumor necrosis factor-alpha (TNF-α) were significantly higher in patients with IIH compared with healthy controls . The serum TNF-α level was a significant predictor of the severity of visual field disease. Interestingly, by evaluating adipokine and cytokine levels to identify possible serum markers of inflammation in the pathophysiology of IIH, it was observed that interleukin (IL)-1β levels were significantly higher in the IIH group compared to the control group, whereas IL-8 and TNF-α levels were significantly lower. Although the latter seems in contrast with previous findings, the presence of recurrent relapses - known to enhance chronic inflammatory protective mechanisms and thus increased TNF- α levels, may explain this difference. Serum levels seem thus to be altered (IL-1β, IL-8 and TNF-α) and may be associated with the pathogenesis of IIH. Cytokines might be valuable as prognostic markers in IIH to predict possible relapse.
Given the established association between increased perivascular expression of the water channel aquaporin-4 (AQP4), degeneration of pericytes, capillary basement membranes, and blood-brain barrier (BBB) dysfunction in patients with IIH, the BBB function was investigated by determining the prevalence of extravasation of endogenous proteins such as fibrinogen. Signs of BBB dysfunction, measured by the surface area of extravasated fibrinogen/fibrin, were significantly more pronounced in IIH patients than in reference subjects and demonstrated BBB dysfunction. The increased degree of BBB dysfunction was associated with increased perivascular AQP4 immunoreactivity. AQP4 appears to play a major role in "flushing" brain parenchyma through interstitial fluid, thus also affecting inflammation-generating substances including fibrinogen extravasation.
Given the obesity of IHH patients, the involvement of leptin, a hormone associated with the sensation of hunger, was also investigated and found to be elevated. Its regulation mechanism of Na/K ATPase in the choroid plexus and CSF secretion has been postulated . It is also important to point out that between 40%-50% of women with IIH suffer from polycystic ovary syndrome, which is characterized by dysregulation of sex hormones . Finally, mineralocorticoids, such as 11β-hydroxysteroid dehydrogenase, have been studied in the pathogenesis of IIH following their potential role in the regulation of Na/K ATPase at the level of the choroid plexus .
Taken together, these studies seem to highlight a wide range of processes for which biomarkers associated with IIH are starting to emerge, but that are still poorly understood. The lack of prospective studies and the small number of patients included in most of the studies carried out so far, impedes conclusions on the role of these factors in the etiology of IIH.
Nevertheless, improvement of IIH treated with acetazolamide and/or stenting seems to correlate with a reduction in ICP, but the association of this reduction with metabolic changes in peripheral, central blood and/or CSF needs to be clarified. The identification of specific inflammatory, immunological and hormonal biomarkers in patients with IIH and their variation in relation to ICP variation should provide a better understanding of its etiology. Biomarkers related to disease severity should allow, in the longer term, proposing alternative treatments.
Advances in endovascular techniques have made it possible to measure ICP at the level of the intracerebral venous system, and to take biological samples at the central (intracerebral) level in order to identify biomarkers associated with clinical severity, and to study their variation as a function of i) normalization of intracranial pressure after treatment with stenting or Diamox, ii) changes in ophthalmological symptoms and headaches.
To date, there are very few prospective cohorts analyzing the biology of patients with IIH. This study will help in the search for biomarkers of the pathology's severity, with a dual aim: 1) to stimulate understanding of the pathophysiology of IIH, which to date remains largely unknown; 2) to develop new drug treatments targeting the mechanisms of increased ICP.
IIH is diagnosed using the modified Dandy criteria,based on increased ICP (\>25 cm H2O on lumbar puncture (LP) performed in the lateral decubitus), papilledema, normal cerebrospinal fluid (CSF) and brain imaging that rules out all other causes of intracranial hypertension.
IIH is attracting growing interest among clinicians as its incidence and prevalence increases. IIH predominates in women of childbearing age with increased body mass index (BMI) . In the United Kingdom its incidence has doubled in 14 years, rising from 3.5 per 100,000 to 7.69 per 100,000 in the female population between 2002 and 2016 (+ 108%)
To date, the exact pathophysiology of IIH remains unknown. IIH is considered to be a complex neurometabolic and neuroendocrine disorder favored by female gender and obesity. Hypothesized mechanisms include inflammatory, autoimmune and hormonal abnormalities, of notably androgens.
In the majority of patients (80% of the cases) IIH is associated with obstruction of cerebral venous drainage with bilateral stenosis of the transverse sinus. This stenosis may be the main underlying cause in the so-called "venogenic" form of IIH. Equally, in the absence of a stenosis, obstruction may occur when otherwise normal venous sinuses are compressed by the increased ICP, the so-called "non-venogenic" form of IIH.
The therapeutic management of IIH has a triple objective: i) to treat the underlying cause(s); ii) to protect vision, and iii) to reduce the impact of headaches. Unfortunately, current treatments (weight loss, drug therapy with acetazolamide or Diamox, and/or anti-migraine treatment) are not very effective. It has been argued to favor treatments targeted directly at the cause of the increased ICP, and therefore at its etiology. A promising innovative treatment of venogenic IIH includes stenting of the transverse sinus stenosis. It has been associated with papilledema and ICP reduction rates up to 80% .
However, venous stenosis is probably not the only underling mechanism of increased ICP. Accordingly, the role of metabolic, hormonal and inflammatory mechanisms requires further investigation. It has been found that serum levels of tumor necrosis factor-alpha (TNF-α) were significantly higher in patients with IIH compared with healthy controls . The serum TNF-α level was a significant predictor of the severity of visual field disease. Interestingly, by evaluating adipokine and cytokine levels to identify possible serum markers of inflammation in the pathophysiology of IIH, it was observed that interleukin (IL)-1β levels were significantly higher in the IIH group compared to the control group, whereas IL-8 and TNF-α levels were significantly lower. Although the latter seems in contrast with previous findings, the presence of recurrent relapses - known to enhance chronic inflammatory protective mechanisms and thus increased TNF- α levels, may explain this difference. Serum levels seem thus to be altered (IL-1β, IL-8 and TNF-α) and may be associated with the pathogenesis of IIH. Cytokines might be valuable as prognostic markers in IIH to predict possible relapse.
Given the established association between increased perivascular expression of the water channel aquaporin-4 (AQP4), degeneration of pericytes, capillary basement membranes, and blood-brain barrier (BBB) dysfunction in patients with IIH, the BBB function was investigated by determining the prevalence of extravasation of endogenous proteins such as fibrinogen. Signs of BBB dysfunction, measured by the surface area of extravasated fibrinogen/fibrin, were significantly more pronounced in IIH patients than in reference subjects and demonstrated BBB dysfunction. The increased degree of BBB dysfunction was associated with increased perivascular AQP4 immunoreactivity. AQP4 appears to play a major role in "flushing" brain parenchyma through interstitial fluid, thus also affecting inflammation-generating substances including fibrinogen extravasation.
Given the obesity of IHH patients, the involvement of leptin, a hormone associated with the sensation of hunger, was also investigated and found to be elevated. Its regulation mechanism of Na/K ATPase in the choroid plexus and CSF secretion has been postulated . It is also important to point out that between 40%-50% of women with IIH suffer from polycystic ovary syndrome, which is characterized by dysregulation of sex hormones . Finally, mineralocorticoids, such as 11β-hydroxysteroid dehydrogenase, have been studied in the pathogenesis of IIH following their potential role in the regulation of Na/K ATPase at the level of the choroid plexus .
Taken together, these studies seem to highlight a wide range of processes for which biomarkers associated with IIH are starting to emerge, but that are still poorly understood. The lack of prospective studies and the small number of patients included in most of the studies carried out so far, impedes conclusions on the role of these factors in the etiology of IIH.
Nevertheless, improvement of IIH treated with acetazolamide and/or stenting seems to correlate with a reduction in ICP, but the association of this reduction with metabolic changes in peripheral, central blood and/or CSF needs to be clarified. The identification of specific inflammatory, immunological and hormonal biomarkers in patients with IIH and their variation in relation to ICP variation should provide a better understanding of its etiology. Biomarkers related to disease severity should allow, in the longer term, proposing alternative treatments.
Advances in endovascular techniques have made it possible to measure ICP at the level of the intracerebral venous system, and to take biological samples at the central (intracerebral) level in order to identify biomarkers associated with clinical severity, and to study their variation as a function of i) normalization of intracranial pressure after treatment with stenting or Diamox, ii) changes in ophthalmological symptoms and headaches.
To date, there are very few prospective cohorts analyzing the biology of patients with IIH. This study will help in the search for biomarkers of the pathology's severity, with a dual aim: 1) to stimulate understanding of the pathophysiology of IIH, which to date remains largely unknown; 2) to develop new drug treatments targeting the mechanisms of increased ICP.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Idiopathic Intracranial Hypertension
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
OTHER
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Idiopathic intracranial hypertension (IHH) patient
IHH patient with bilateral stenosis of the transversal sinus
Group Type
EXPERIMENTAL
Blood punction
Intervention Type
PROCEDURE
Peripheral blood sampling (5 ml) at inclusion and 3 months after treatment
Central blood sampling
Intervention Type
PROCEDURE
Central blood sampling (2 ml) at inclusion and 3 months after treatment
Intracranial pressure measurement
Intervention Type
PROCEDURE
Intracranial pressure measurement at sinus level with micro-catheter at inclusion and 3 months after treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood punction
Peripheral blood sampling (5 ml) at inclusion and 3 months after treatment
Intervention Type
PROCEDURE
Central blood sampling
Central blood sampling (2 ml) at inclusion and 3 months after treatment
Intervention Type
PROCEDURE
Intracranial pressure measurement
Intracranial pressure measurement at sinus level with micro-catheter at inclusion and 3 months after treatment
Intervention Type
PROCEDURE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years and older
* Patients with newly diagnosed untreated HII (following the modified Dandy criteria) with normal CSF composition, abnormal CSF pressure at the lumbar puncture (\>25 cm H2O), and significant pressure gradient at the level of the stenosis (≥8 mmHg)
* Presence of bilateral transverse sinus stenosis (or unilateral with hypoplastic contralateral sinus).
* Patients with newly diagnosed untreated HII (following the modified Dandy criteria) with normal CSF composition, abnormal CSF pressure at the lumbar puncture (\>25 cm H2O), and significant pressure gradient at the level of the stenosis (≥8 mmHg)
* Presence of bilateral transverse sinus stenosis (or unilateral with hypoplastic contralateral sinus).
Exclusion Criteria
* Allergy to contrast media (nickel, titanium)
* Allergy or contraindication to antiplatelet agents
* Patient on anti-inflammatory treatment
* Chronic inflammatory disease
* History of intracranial venous thrombosis, cerebral hemorrhage, thrombophilia
* History of intracranial tumor
* Fulminant IIH with acute visual loss
* Optic nerve atrophy with papilledema (chronic IIH)
* Female being pregnant, breastfeeding, or planning to become pregnant in the next 3 months
* Major comorbidities with high procedural risk
* Life expectancy \< 6 months
* Adult under guardianship or conservatorship or incapacitated
* Refusal of consent after receiving all necessary information
* Not covered by or not a beneficiary of the French social security system
* Allergy or contraindication to antiplatelet agents
* Patient on anti-inflammatory treatment
* Chronic inflammatory disease
* History of intracranial venous thrombosis, cerebral hemorrhage, thrombophilia
* History of intracranial tumor
* Fulminant IIH with acute visual loss
* Optic nerve atrophy with papilledema (chronic IIH)
* Female being pregnant, breastfeeding, or planning to become pregnant in the next 3 months
* Major comorbidities with high procedural risk
* Life expectancy \< 6 months
* Adult under guardianship or conservatorship or incapacitated
* Refusal of consent after receiving all necessary information
* Not covered by or not a beneficiary of the French social security system
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Montpellier
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Federico CAGNAZZO, MD
Role: STUDY_DIRECTOR
University Hospital of Montpellier - Gui de Chauliac
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Montpellier - Gui de Chauliac
Montpellier, , France
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
France
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Markey KA, Mollan SP, Jensen RH, Sinclair AJ. Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurol. 2016 Jan;15(1):78-91. doi: 10.1016/S1474-4422(15)00298-7. Epub 2015 Dec 8.
Reference Type
BACKGROUND
Mollan SP, Aguiar M, Evison F, Frew E, Sinclair AJ. The expanding burden of idiopathic intracranial hypertension. Eye (Lond). 2019 Mar;33(3):478-485. doi: 10.1038/s41433-018-0238-5. Epub 2018 Oct 24.
Reference Type
BACKGROUND
Riggeal BD, Bruce BB, Saindane AM, Ridha MA, Kelly LP, Newman NJ, Biousse V. Clinical course of idiopathic intracranial hypertension with transverse sinus stenosis. Neurology. 2013 Jan 15;80(3):289-95. doi: 10.1212/WNL.0b013e31827debd6. Epub 2012 Dec 26.
Reference Type
BACKGROUND
Toscano S, Lo Fermo S, Reggio E, Chisari CG, Patti F, Zappia M. An update on idiopathic intracranial hypertension in adults: a look at pathophysiology, diagnostic approach and management. J Neurol. 2021 Sep;268(9):3249-3268. doi: 10.1007/s00415-020-09943-9. Epub 2020 May 27.
Reference Type
BACKGROUND
Dhungana S, Sharrack B, Woodroofe N. Cytokines and chemokines in idiopathic intracranial hypertension. Headache. 2009 Feb;49(2):282-5. doi: 10.1111/j.1526-4610.2008.001329.x.
Reference Type
BACKGROUND
Zanello SB, Tadigotla V, Hurley J, Skog J, Stevens B, Calvillo E, Bershad E. Inflammatory gene expression signatures in idiopathic intracranial hypertension: possible implications in microgravity-induced ICP elevation. NPJ Microgravity. 2018 Jan 11;4:1. doi: 10.1038/s41526-017-0036-6. eCollection 2018.
Reference Type
BACKGROUND
Nicholson P, Brinjikji W, Radovanovic I, Hilditch CA, Tsang ACO, Krings T, Mendes Pereira V, Lenck S. Venous sinus stenting for idiopathic intracranial hypertension: a systematic review and meta-analysis. J Neurointerv Surg. 2019 Apr;11(4):380-385. doi: 10.1136/neurintsurg-2018-014172. Epub 2018 Aug 30.
Reference Type
BACKGROUND
Fahmy EM, Rashed LA, Mostafa RH, Ismail RS. Role of tumor necrosis factor-alpha in the pathophysiology of idiopathic intracranial hypertension. Acta Neurol Scand. 2021 Nov;144(5):509-516. doi: 10.1111/ane.13482. Epub 2021 Jun 15.
Reference Type
BACKGROUND
Samanci B, Samanci Y, Tuzun E, Altiokka-Uzun G, Ekizoglu E, Icoz S, Sahin E, Kucukali CI, Baykan B. Evidence for potential involvement of pro-inflammatory adipokines in the pathogenesis of idiopathic intracranial hypertension. Cephalalgia. 2017 May;37(6):525-531. doi: 10.1177/0333102416650705. Epub 2016 May 18.
Reference Type
BACKGROUND
Hasan-Olive MM, Hansson HA, Enger R, Nagelhus EA, Eide PK. Blood-Brain Barrier Dysfunction in Idiopathic Intracranial Hypertension. J Neuropathol Exp Neurol. 2019 Sep 1;78(9):808-818. doi: 10.1093/jnen/nlz063.
Reference Type
BACKGROUND
Eide PK, Eidsvaag VA, Nagelhus EA, Hansson HA. Cortical astrogliosis and increased perivascular aquaporin-4 in idiopathic intracranial hypertension. Brain Res. 2016 Aug 1;1644:161-75. doi: 10.1016/j.brainres.2016.05.024. Epub 2016 May 14.
Reference Type
BACKGROUND
Ball AK, Sinclair AJ, Curnow SJ, Tomlinson JW, Burdon MA, Walker EA, Stewart PM, Nightingale PG, Clarke CE, Rauz S. Elevated cerebrospinal fluid (CSF) leptin in idiopathic intracranial hypertension (IIH): evidence for hypothalamic leptin resistance? Clin Endocrinol (Oxf). 2009 Jun;70(6):863-9. doi: 10.1111/j.1365-2265.2008.03401.x. Epub 2008 Sep 2.
Reference Type
BACKGROUND
Markey KA, Uldall M, Botfield H, Cato LD, Miah MA, Hassan-Smith G, Jensen RH, Gonzalez AM, Sinclair AJ. Idiopathic intracranial hypertension, hormones, and 11beta-hydroxysteroid dehydrogenases. J Pain Res. 2016 Apr 19;9:223-32. doi: 10.2147/JPR.S80824. eCollection 2016.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RECHMPL22_0565
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Defining Volume Status with Extracellular Water Measurement in Patients with Intracranial Hemorrhage
NCT06590688
NOT_YET_RECRUITING
Coagulation Activation by Hyperosmolar Agents in Intracranial Hypertension
NCT03409237
WITHDRAWN
A Non-invasive Intracranial Pressure (nICP) Monitoring System
NCT05632302
COMPLETED
NA
Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.
NCT02017444
COMPLETED
PHASE2
Pituitary Function and Spontaneous Intracranial Hypotension
NCT02603549
SUSPENDED
Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment
NCT06361823
NOT_YET_RECRUITING
PHASE3
Hidden Impairments During Subarachnoid Haemorrhage Recovery, Description and Evolution of a Newly Described Syndrom
NCT06276517
NOT_YET_RECRUITING
Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines
NCT02059941
UNKNOWN
Relationship Between Intracranial Blood Flow and Peripheral Perfusion in Patients With Craniocerebral Injury
NCT06016751
COMPLETED
Study of Changes in CSF Ionic Composition After Aneurysmal Meningeal Hemorrhage
NCT05942755
UNKNOWN
Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial
NCT00963976
COMPLETED
PHASE2
Comparison of 2 Doses of Mannitol on Post Traumatic Intracranial Hypertension and Cerebral Monitoring
NCT00795587
TERMINATED
PHASE4
Intracranial Pressure Monitoring in Sever Traumatic Brain Injury Single Center Experience
NCT03721003
UNKNOWN
Blood Pressure Treatment in ICU Patients with Subarachniodal Haemorrhage.
NCT06033378
RECRUITING
NA
Multimodal Monitoring Study in Neuro Critical Care
NCT06900101
RECRUITING
Pathophysiology and Treatment of Cerebrospinal Hypotension Exploration Study
NCT06805591
ENROLLING_BY_INVITATION
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
NCT06402968
RECRUITING
Prospective Evaluation of the Non-invasive ICP HeadSense Monitor in TBI Patients Undergoing Invasive ICP Monitoring
NCT02773862
COMPLETED
NA
Greater Occipital Nerve Block for Spontaneous Intracranial Hypotension
NCT06374524
RECRUITING
Non-Invasive ICP Monitoring Study
NCT07113353
NOT_YET_RECRUITING
Impact of Cardiac Blood Flow on Cerebral Blood Flow in Patients With Severe Traumatic Brain Injury
NCT02019810
UNKNOWN
PHASE2
Systemic Normothermia in Intracerebral Hemorrhage (ICH)
NCT02078037
COMPLETED
EARLY_PHASE1
Intracranial Pressure (ICP) Monitoring Following Traumatic Brain Injury (TBI)
NCT04428970
COMPLETED
Association Between Haptoglobin Genotype and Brain Swelling
NCT02054117
TERMINATED